01 enero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Side Branch Occlusion After Bioresorbable Vascular Scaffold Implantation. Lessons From Optimal Coherence Tomography

Katsumasa Sato, MD∗; Vasileios F. Panoulas, PhD∗; Hiroyoshi Kawamoto, MD∗; Toru Naganuma, MD∗; Tadashi Miyazaki, MD∗; Azeem Latib, MD∗; Antonio Colombo, MD∗

There are limited data regarding the side branch occlusion (SBO) after Absorb bioresorbable everolimus-eluting vascular scaffolds (BVS) 1.1 (Abbott Vascular, Santa Clara, California). Even though the second-generation BVS 1.1 has improved on the design of BVS 1.0, the increased strut thickness and width remain and potentially more frequently compromise small SB as compared to the new-generation drug-eluting stents with thin strut. A previous study 1 demonstrated that BVS had a higher incidence (10.5%) of post-procedural SBO compared with the everolimus-eluting metallic stent for SB with a reference vessel diameter ≤0.5 mm. Regarding SB with a reference vessel diameter of ≥1.0 mm, however, the incidence of SBO in the BVS group was similar to that in the everolimus-eluting metallic stent group (1.7% vs. 2.2%, p = 0.61).

01 enero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Increasing Percutaneous Coronary Interventions for ST-Segment Elevation Myocardial Infarction in the United States. Progress and Opportunity

Rashmee U. Shah, MD, MS∗; Timothy D. Henry, MD†; Stephanie Rutten-Ramos, DVM, PhD; Ross F. Garberich, MS‡; Mourad Tighiouart, PhD†; C. Noel Bairey Merz, MD†

Objectives: The aim of this study was to quantify changes in percutaneous coronary intervention (PCI) and mortality rates for ST-segment elevation myocardial infarction (STEMI), and the proportion of hospitals providing STEMI-related PCI in the United States.

01 enero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Double-Blind, Randomized, Prospective Comparison of Loading Doses of 600 mg Clopidogrel Versus 60 mg Prasugrel in Patients With Acute ST-Segment Elevation Myocardial Infarction Scheduled for Primary Percutaneous Intervention. The ETAMI Trial (Early Thienopyridine treatment to improve primary PCI in Patients with Acute Myocardial Infarction)

Uwe Zeymer, MD∗; Hans-Christian Mochmann, MD†; Bernd Mark, MD‡; Hans-Richard Arntz, MD†; Holger Thiele, MD§; Frank Diller‖; Gilles Montalescot, MD¶; Ralf Zahn, MD‡

Objectives: This study compared the timing of onset of antiplatelet action after treatment with clopidogrel and prasugrel at first medical contact in patients with ST-segment elevation myocardial infarction (STEMI) scheduled for primary percutaneous coronary intervention (PPCI).

01 enero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Prophylactic Warfarin Therapy After Primary Percutaneous Coronary Intervention for Anterior ST-Segment Elevation Myocardial Infarction

Michel R. Le May, MD; Sudikshya Acharya, BSc; George A. Wells, PhD; Ian Burwash, MD; Aun Yeong Chong, MD; Derek Y. So, MD; Chris A. Glover, MD; Michael P.V. Froeschl, MD; Benjamin Hibbert, MD; Jean-François Marquis, MD; Alexander Dick, MD; Melissa Blondeau, BSc; Jordan Bernick, MSc; Marino Labinaz, MD

Objectives: This study sought to determine the benefits of adding oral anticoagulation therapy in patients with anterior wall ST-segment elevation myocardial infarction (STEMI) patients after primary percutaneous coronary intervention (PCI).

01 enero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Relationship Between Time to Invasive Assessment and Clinical Outcomes of Patients Undergoing an Early Invasive Strategy After Fibrinolysis for ST-Segment Elevation Myocardial Infarction. A Patient-Level Analysis of the Randomized Early Routine Invasive Clinical Trials

Mina Madan, MD∗; Sigrun Halvorsen, MD†; Carlo Di Mario, MD‡; Mary Tan, MSc§; Cynthia M. Westerhout, PhD‖; Warren J. Cantor, MD¶; Michel R. Le May, MD#; Francesco Borgia, MD∗∗; Federico Piscione, MD††; Bruno Scheller, MD‡‡; Paul W. Armstrong, MD‖; Francisco Fernandez-Aviles, MD§§; Pedro L. Sanchez, MD§§; John J. Graham, MD‖‖; Andrew T. Yan, MD‖‖; Shaun G. Goodman, MD§

Objectives: This study investigated the relationship between time to invasive assessment and outcomes among ST-segment elevation myocardial infarction patients randomized to early angiography after fibrinolysis.

01 enero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Remote Ischemic Conditioning Reduces Myocardial Infarct Size and Edema in Patients With ST-Segment Elevation Myocardial Infarction

Steven K. White, MD∗; Georg M. Frohlich, MD†; Daniel M. Sado, MD†; Viviana Maestrini, MD†; Marianna Fontana, MD†; Thomas A. Treibel, MBBS†; Shana Tehrani, MD†; Andrew S. Flett, MD‡; Pascal Meier, MD†; Cono Ariti, MSc§; John R. Davies, PhD‖; James C. Moon, MD†; Derek M. Yellon, DSc, PhD∗; Derek J. Hausenloy, MD, PhD∗

Objectives: This study aimed to determine whether remote ischemic conditioning (RIC) initiated prior to primary percutaneous coronary intervention (PPCI) could reduce myocardial infarct (MI) size in patients presenting with ST-segment elevation myocardial infarction.

01 enero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Absorb Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent in ST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity Score Matching Comparison. The BVS-EXAMINATION Study (Bioresorbable Vascular Scaffold-A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction)

Salvatore Brugaletta, MD, PhD∗; Tommaso Gori, MD, PhD†; Adrian F. Low, MBBS‡; Petr Tousek, MD, PhD§; Eduardo Pinar, MD, PhD‖; Josep Gomez-Lara, MD, PhD¶; Giancarla Scalone, MD∗; Eberhard Schulz, MD†; Mark Y. Chan, MBBS, MPH‡; Viktor Kocka, MD§; Jose Hurtado, MD‖; Juan Antoni Gomez-Hospital, MD, PhD¶; Thomas Münzel, MD†; Chi-Hang Lee, MBBS, MD‡; Angel Cequier, MD, PhD¶; Mariano Valdés, MD‖; Petr Widimsky, MD, DrSc§; Patrick W. Serruys, MD, PhD#; Manel Sabaté, MD, PhD∗

Objectives: The purpose of this study was to compare the 1-year outcome between bioresorbable vascular scaffold (BVS) and everolimus-eluting metallic stent (EES) in ST-segment elevation myocardial infarction (STEMI) patients.

01 enero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Comprehensive Meta-Analysis of Safety and Efficacy of Bivalirudin Versus Heparin With or Without Routine Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndrome

Eliano Pio Navarese, MD, PhD∗; Volker Schulze, MD†; Felicita Andreotti, MD, PhD‡; Mariusz Kowalewski, MD‡; Michalina Kołodziejczak, MD‡; David E. Kandzari, MD#; Tienush Rassaf, MD, PhD†; Bartosz Gorny, MD‡; Maximilian Brockmeyer, MD†; Christian Meyer, MD, PhD†; Sergio Berti, MD∗; Jacek Kubica, MD, PhD‡; Malte Kelm, MD†; Marco Valgimigli, MD, PhD††

Objectives: The aim of this meta-analysis was to compare the 30-day safety and efficacy of bivalirudin with those of heparin with or without routine administration of a glycoprotein IIb/IIIa inhibitor (GPI) in patients with acute coronary syndrome (ACS).

01 enero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Acute Stent Thrombosis After Primary Percutaneous Coronary Intervention. Insights From the EUROMAX Trial (European Ambulance Acute Coronary Syndrome Angiography)

Peter Clemmensen, MD, DMSc∗; Sebastian Wiberg, MD†; Arnoud van´t Hof, MD, PhD‡; Efthymios N. Deliargyris, MD§; Pierre Coste, MD‖; Jurrien ten Berg, MD¶; Claudio Cavallini, MD#; Martial Hamon, MD∗∗; Dariusz Dudek, MD††; Uwe Zeymer, MD‡‡; Xavier Tabone, MD§§; Steen D. Kristensen, MD, DMSc‖‖; Debra Bernstein, PhD§; Prodromos Anthopoulos, MD§; Jayne Prats, PhD§; Philippe Gabriel Steg, MD¶¶

Objectives: This study sought to determine clinical, procedural, and treatment factors associated with acute stent thrombosis (AST) in the EUROMAX (European Ambulance Acute Coronary Syndrome Angiography) trial.

01 febrero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Percutaneous Circulatory Assist Devices for High-Risk Coronary Intervention CME

Aung Myat, MBBS∗; Niket Patel, MBBS†; Shana Tehrani, MD‡; Adrian P. Banning, MD, PhD†; Simon R. Redwood, MD∗; Deepak L. Bhatt, MD, MPH§

A unifying definition of what constitutes high-risk percutaneous coronary intervention remains elusive. This reflects the existence of several recognized patient, anatomic, and procedural characteristics that, when combined, can contribute to elevating risk. The relative inability to withstand the adverse hemodynamic sequelae of dysrhythmia, transient episodes of ischemia-reperfusion injury, or distal embolization of atherogenic material associated with coronary intervention serve as a common thread to tie this patient cohort together. This enhanced susceptibility to catastrophic hemodynamic collapse has triggered the development of percutaneous cardiac assist devices such as the intra-aortic balloon pump, Impella (Abiomed Inc., Danvers, Massachusetts), TandemHeart (CardiacAssist, Inc., Pittsburgh, Pennsylvania), and extracorporeal membranous oxygenation to provide adjunctive mechanical circulatory support. In this state-of-the-art review, we discuss the physiology underpinning their application. Thereafter, we examine the results of several randomized multicenter trials investigating their use in high-risk coronary intervention to determine which patients would benefit most from their implantation and whether there is a signal to delineate whether they should be used in an elective pre-procedure, standby, rescue, or routine post-procedure fashion.

01 febrero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Procedural Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention. A Report From the NCDR (National Cardiovascular Data Registry)

Emmanouil S. Brilakis, MD, PhD∗; Subhash Banerjee, MD∗; Dimitri Karmpaliotis, MD†; William L. Lombardi, MD‡; Thomas T. Tsai, MD, MSc§; Kendrick A. Shunk, MD, PhD‖; Kevin F. Kennedy, MS¶; John A. Spertus, MD¶; David R. Holmes, MD#; J. Aaron Grantham, MD¶

Objectives: The aim of this study was to describe contemporary frequency, predictors, and outcomes of chronic total occlusion (CTO) percutaneous coronary intervention (PCI) in the United States.

01 febrero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Coronary Computed Tomographic Prediction Rule for Time-Efficient Guidewire Crossing Through Chronic Total Occlusion. Insights From the CT-RECTOR Multicenter Registry (Computed Tomography Registry of Chronic Total Occlusion Revascularization)

Maksymilian P. Opolski, MD∗; Stephan Achenbach, MD‡; Annika Schuhbäck, MD‡; Andreas Rolf, MD∗; Helge Möllmann, MD∗; Holger Nef, MD§; Johannes Rixe, MD§; Matthias Renker, MD§; Adam Witkowski, MD†; Cezary Kepka, MD‖; Claudia Walther, MD∗; Christian Schlundt, MD‡; Artur Debski, MD†; Michal Jakubczyk, MSc¶; Christian W. Hamm, MD∗

Objectives: This study sought to establish a coronary computed tomography angiography prediction rule for grading chronic total occlusion (CTO) difficulty for percutaneous coronary intervention (PCI).

01 febrero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Long-Term Survival Benefit of Revascularization Compared With Medical Therapy in Patients With Coronary Chronic Total Occlusion and Well-Developed Collateral Circulation

Woo Jin Jang, MD∗; Jeong Hoon Yang, MD, PhD∗; Seung-Hyuk Choi, MD, PhD∗; Young Bin Song, MD, PhD∗; Joo-Yong Hahn, MD, PhD∗; Jin-Ho Choi, MD, PhD∗; Wook Sung Kim, MD, PhD†; Young Tak Lee, MD, PhD†; Hyeon-Cheol Gwon, MD, PhD∗

Objectives: The purpose of this study was to compare the long-term clinical outcomes of patients with chronic total occlusion (CTO) and well-developed collateral circulation treated with revascularization versus medical therapy.

01 febrero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Real-Time Ultrasound Guidance Facilitates Transradial Access. RAUST (Radial Artery Access With Ultrasound Trial)

Arnold H. Seto, MD, MPA∗; Jonathan S. Roberts, MD‡; Mazen S. Abu-Fadel, MD§; Steven J. Czak, DO∥; Faisal Latif, MD§; Suresh P. Jain, MD∥; Jaffar A. Raza, MD∥; Aditya Mangla, DO∥; Georgia Panagopoulos, PhD∥; Pranav M. Patel, MD†; Morton J. Kern, MD∗; Zoran Lasic, MD∥

Objectives: This study sought to assess the utility of ultrasound (US) guidance for transradial arterial access.

01 febrero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Pre-Treatment With Glucagon-Like Peptide-1 Protects Against Ischemic Left Ventricular Dysfunction and Stunning Without a Detected Difference in Myocardial Substrate Utilization

Liam M. McCormick, MBBS∗; Stephen P. Hoole, MA, DM†; Paul A. White, PhD‡; Philip A. Read, MA, MD†; Richard G. Axell, MSc‡; Sophie J. Clarke, BSc∗; Michael O’Sullivan, PhD†; Nick E.J. West, MA, MD†; David P. Dutka, MA, DM∗

Objectives: This study sought to determine whether pre-treatment with intravenous glucagon-like peptide-1 (GLP-1)(7-36) amide could alter myocardial glucose use and protect the heart against ischemic left ventricular (LV) dysfunction during percutaneous coronary intervention.